drugset / Trial / NCT07673029
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
Timeline
- Start
- 2025-01-10
- Primary completion
- 2027-01-09
- Completion
- 2028-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GQ1005 | Other / unclassified | — | Intravenous |
| Subject | Trastuzumab emtansine | Other / unclassified | — | Intravenous |